Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07639021

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Isis Clinical Res. Ctr P.S.C., Guaynabo, Puerto Rico

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or above at the time of signing the informed consent.
  • Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m^2) at screening.
  • Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.

Exclusion criteria

  • Known or suspected hypersensitivity to study intervention(s) or related products.
  • Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.
  • Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus.

Treatment and study plan

NNC0662-0419

Drug

NNC0662-0419 will be administered subcutaneously.

semaglutide

Drug

Semaglutide will be administered subcutaneously.

NNC0662-0419 Placebo

Drug

Placebo matched to NNC0662-0419 will be administered subcutaneously.

Semaglutide Placebo

Drug

Placebo matched to semaglutide will be administered subcutaneously.

Primary outcomes

  1. Number of gastrointestinal adverse events

    Time frame: From week 0 to week 39

    Measured as number of events.

Secondary outcomes

  1. Relative change in body weight

    Time frame: From week 0 to week 32

    Measured as percentage (%) change.

  2. Change in body mass index (BMI)

    Time frame: From week 0 to week 32

    Measured as kilogram per square meter (kg/m^2).

Study contacts

Contact information is provided by the study sponsor or research team.

Novo Nordisk

CONTACT

[email protected]

(+1) 866-867-7178

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 10, 2026
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.